Typhi Omp-specific adaptive immune responses evolve over a period of at least two months after vaccination. == Materials and methods == == Subjects, vaccination and sample collection == This open, interventional study was approved by the Ethics Commission of the Canton St. in stool peaked at day 60. Similarly, Omp-specific CD4+T cells in peripheral blood showed the highest expansion at day 60 post vaccination, concomitant with a significant increase in IFN- and TNF production. These results indicate thatS. Typhi Omp-specific B cell responses and polyfunctional CD4+T cell responses evolve KDR antibody over a period of at least two months after application of the live attenuated vaccine. Moreover, these findings underscore the potential ofS. Typhi Omps as subunit vaccine components. Trial registration:ISRCTN18360696 == Introduction == Salmonellaenterica serovar Typhi (S. Typhi) is an orally transmitted bacterial pathogen that infects only humans. Protective immune responses against this pathogen include the conversation of innate and adaptive immune mechanisms [1,2]. Due to the host restriction, studies on disease pathogenesis and immune protection in the natural host are limited [3]. The Ty21a live attenuated vaccine strain represents a valuable model for studying immune responses that develop during contamination with typhoidalSalmonella[3,4]. Indeed, several studies have explained the induction of humoral and cellular immune responses against different components of Ty21a after vaccination of healthy volunteers [511]. For example, IgM, IgG and IgA antibodies against membrane proteins can be detected in the plasma of healthy individuals even before the vaccination. However, ex vivo cultures of lymphocytes obtained early after Ty21a vaccination revealed higher levels of specific antibodies in supernatants compared to controls indicating that systemic B cell responses are swiftly activated after encounter of Salmonella antigens [6]. Antibodies against the O-9,12 antigen, plasmablasts specific for lipopolysaccharide (LPS), and flagellin [6,7,12] can be detected in circulation as early as day 7 after vaccination. Examination of immune cell properties revealed thatS. Typhi-specific T cells bear homing receptors for intestinal tissues [8,11], while the induction effector memory CD8+T cells by Ty21a vaccination [13] suggests that cytotoxic T cell responses Gamitrinib TPP hexafluorophosphate could at least in part contribute to the protection exerted by the vaccine. Furthermore, cross-reactive cellular immune responses include multifunctional CD4+and CD8+T cells [8,10,14] underscoring the importance of multiple layers of immune mechanisms involved in the protection against this bacterial infection [15]. However, a broad range of immune responses directed against different target structures is not always advantageous for the host. For example, dysregulated B cell responses against LPS favor replication of non-typhoidalSalmonellain human immunodeficiency computer virus (HIV)-infected individuals leading to reduced bactericidal activity of antibodies against normally protective bacterial antigens [16]. Hence, it is important to analyze the development of immune responses directed against protective antigens such as flagellin [17] or outer membrane proteins (Omps) [16] in the context of complex antigenic exposure such as vaccination with a live attenuated pathogen. Pore-forming Omps (also known as porins) represent important antigenic targets for an efficient response againstSalmonella. The immune response against these proteins is usually shaped in the beginning through the direct TLR-dependent activation of antigen presenting cells [18]. Subsequently, porin-specific CD4+T cells promote protective antibody responses via production of IFN- and other cytokines [19]. Individuals recovering from typhoid fever possess circulating IgG and IgM antibodies against porins [20] and purifiedS. Typhi OmpC and F, which form the major Omp fractions ofS. Typhi, and induce IgM and IgG bactericidal antibodies in mice and humans [19,21]. A vaccine candidate based on purifiedS. Typhi OmpC and F has been tested in a clinical trial exposing security and immunogenicity following subcutaneous application [22]. Currently, novel formulations ofS. Typhi porins for oral application are under investigation using Gamitrinib TPP hexafluorophosphate encapsulation into biocompatible copolymers of lactic and glycolic acid (PLGA) microparticles rendering the proteins resistant to gastric acids [23]. To follow the development ofS. Typhi OmpC and F-specific T and B cell responses in the natural host, we vaccinated healthy volunteers with the live attenuated vaccine strain Ty21a [24]. We found a significant increase in antibody-secreting cells present in peripheral blood and maximal serum IgG titers at day 25 post vaccination. Interestingly, Gamitrinib TPP hexafluorophosphate both IgA titers in stool and Omp-specific polyfunctional CD4+T cells in peripheral blood peaked at day 60 indicating thatS. Typhi Omp-specific adaptive immune responses evolve over a period of at least two months after vaccination. == Materials and methods == == Subjects, vaccination and sample collection == This open, interventional study was approved by the Ethics Commission rate of the Canton St. Gallen (EKSG 15/085) and has been published as ISRCTN18360696 (DOI 10.1186/ISRCTN18360696). Before enrolment, subjects were informed about the purpose.